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Background: A limited number of nondigestible oligosaccharides are available for use in infant formula. This
study evaluated growth and safety in infants fed formula supplemented with a mixture of bovine milk-derived
oligosaccharides (BMOS). This mixture, which was generated from whey permeate, contains galactooligosaccharides
and other oligosaccharides from bovine milk, such as 3′- and 6′-sialyllactose. We hypothesized that growth in
infants fed BMOS-supplemented formula would be noninferior to that in infants fed standard formula.
Methods: Healthy term infants ≤14 days old were randomly assigned to standard formula (control; n = 84);
standard formula with BMOS (IF-BMOS; n = 99); or standard formula with BMOS and probiotics (Bifidobacterium longum,
Lactobacillus rhamnosus) (IF-BMOS + Pro; n = 98). A breastfed reference group was also enrolled (n = 30). The primary
outcome was mean weight gain/day from enrollment to age 4 months (noninferiority margin: −3.0 g/day).
Results: 189 (67.3%) formula-fed infants were included in the primary analysis. Mean differences in weight gain
between the control and IF-BMOS and IF-BMOS + Pro groups were <1 g/day, with 97.5% confidence intervals
above −3.0 g/day, indicating noninferior weight gain in the BMOS formula groups. Compared with control, infants in
the BMOS groups had more frequent (p < 0.0001) and less hard (p = 0.0003) stools. No significant differences were
observed between the control and BMOS groups in caregivers’ reports of flatulence, vomiting, spitting up, crying,
fussing, and colic. When based on clinical evaluation by the investigator, the incidence of colic was higher (p = 0.01) in
IF-BMOS than in control; the incidence of investigator-diagnosed colic was not significantly different in control and
IF-BMOS + Pro (p = 0.15). Stool bifidobacteria and lactobacilli counts were higher with IF-BMOS + Pro compared with
control (p < 0.05), whereas Clostridia counts were lower (p < 0.05) in both BMOS groups compared with control.
Conclusions: Infant formula containing BMOS either with or without probiotics provides adequate nutrition for normal
growth in healthy term infants. Further studies are needed to fully explore the digestive tolerance of BMOS formula.
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Human milk is widely recognized as the optimal source of
nutrition for infants. Greater scientific understanding of
the beneficial components and properties of human milk
has contributed to improvements in infant formula for in-
fants who are either partially or exclusively formula-fed.
The bifidogenic properties of human milk are of par-
ticular interest, based on evidence that a bifidobacteria-
predominant gut microbiota may reduce the risk of
infections and allergies in infants [1-4]. Efforts to achieve
similar benefits in infants who receive formula have largely
focused on the addition of either probiotics or prebiotics,
or both, to infant formula. Probiotics are live bacteria
(often bifidobacteria and lactobacilli species) considered to
have beneficial health effects [1,2]. Prebiotics are oligosac-
charides that pass undigested through the small intestine
in humans and are then selectively digested by potentially
beneficial bacteria in the colon, such as bifidobacteria [5].
Human milk is rich in non-digestible oligosaccharides,
which may play an important role in supporting the
bifidobacteria-predominant gut microbiota observed in
breastfed infants [6-8]. Non-digestible oligosaccharides
in human milk may have other beneficial effects as well.
Some human milk oligosaccharides have been shown to
directly bind to pathogenic bacteria, inhibiting the attach-
ment of these pathogens to host cells [6]. In addition,
microbial fermentation of non-digestible oligosaccharides
in the gut contributes to an acidic environment that may
inhibit the growth of pathogens [3,5,6]. As a result of these
activities, non-digestible human milk oligosaccharides
are believed to play a key role in the establishment of a
healthy intestinal microbiota that provides resistance to
pathogen colonization [9].
Currently, the use of prebiotics in infant formulae is
limited to three primary types of oligosaccharides: 1)
galactooligosaccharides (GOS), which are elongations of
lactose by galactose; 2) inulins, which are elongations of
sucrose by fructose; and 3) fructooligosaccharides (FOS),
which may be either elongations of sucrose by fructose
or partially hydrolyzed inulin. In contrast, human milk
contains more than 200 oligosaccharide structures that
are elongations of lactose by N-acetyl-glucosamine
and galactose with or without terminal fucose and si-
alic acid moieties [10,11]. A number of human milk
oligosaccharides have been shown to have bifidogenic
properties [12,13].
The lack of diversity in oligosaccharides available for
use in infant formula has resulted from technical chal-
lenges in obtaining oligosaccharide structures similar to
those in human milk [14]. Bovine milk contains oligosac-
charides, some of which are structurally identical or simi-
lar to those found in human milk [15,16]. This suggests
that oligosaccharides derived from bovine milk may
provide some of the beneficial properties associated withhuman milk oligosaccharides. However, until recently the
low concentrations of these oligosaccharides in bovine
milk (approximately 20-fold lower than in human milk
[14]) have hampered efforts to utilize bovine milk as a
source of oligosaccharides for infant formula.
The present study evaluated infant formula supplemen-
ted with a mixture of bovine milk-derived oligosaccharides
(BMOS). This mixture, which was generated from whey
permeate, contained galactooligosaccharides and other
oligosaccharides from bovine milk, such as 3′- and 6′-
sialyllactose. Two BMOS-containing formulae were evalu-
ated: one was supplemented with BMOS only; the other
was supplemented with BMOS and the probiotics Bifido-
bacterium longum (Bl999) and Lactobacillus rhamnosus
(LPR). The primary goal of the study was to evaluate
growth and safety in infants fed the BMOS-supplemented
formulae. We hypothesized that growth in infants fed
BMOS-supplemented formulae would be noninferior to
that in infants fed standard formula. We also explored the
effects of BMOS-supplemented formulae on stooling
outcomes and the composition of the gut microbiota.
Methods
Study design
This randomized, double-blind, single-center trial was con-
ducted in 2007–2008 in Palermo, Italy at the Università
degli Studi di Palermo, Dipartimento Materno Infantile,
Unità Operativa di Neonatologia. The study was ap-
proved by the independent ethics committee of this
institution and conducted in accordance with Good
Clinical Practice and the principles and rules of the
Declaration of Helsinki. The infants’ parents or legal guar-
dians provided written informed consent prior to enroll-
ment in the study.
Population
Healthy, full-term, newborn infants were recruited from
the study center during visits for routine perinatal care.
Infants whose mothers had chosen to not breastfeed
beyond age 14 days were randomized into the formula
groups. Infants whose mothers intended to breastfeed
from birth through at least age 4 months were enrolled
in a nonrandomized reference group. Inclusion criteria
were age ≤14 days at enrollment, weight 2500–4500 g,
gestational age ≥37 weeks at birth, and singleton preg-
nancy. Exclusion criteria included any congenital illness or
malformation that could affect normal growth, any signifi-
cant pre- or postnatal disease, re-hospitalization for more
than 2 days during the first 14 days of life, or anti-
biotic use at any time during the 5 days prior to study
enrollment.
Randomization was conducted using a computer-
generated randomization list with stratification by sex
and delivery mode (natural or caesarian). Investigators
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computerized randomization system on a centralized
server.
Study formulae
The study formulae contained sufficient amounts of
proteins, carbohydrates, fats, vitamins, and minerals for
normal growth of infants from birth to age 6 months.
Study formulae also contained long chain polyunsatur-
ated fatty acids and provided 67 kcal/100 ml of reconsti-
tuted formula and 1.8 g of protein/100 kcal. The control
formula was a standard, commercially available whey-
based infant formula (NAN 1, Nestlé Nutrition, Nestec
Ltd., Vevey, Switzerland). The two BMOS-supplemented
formulae (developed at Nestlé Product Technology Center,
Konolfingen, Switzerland) were similar in composition to
the control formula except: a) one formula (IF-BMOS)
contained BMOS at a total oligosaccharide concentration
of 7.3 ± 1.0 g/100 g of powder formula (10 g/L in the re-
constituted formula) replacing the equivalent amount of
lactose in the control formula; and b) the other formula
(IF-BMOS + Pro) contained BMOS (7.3 ± 1.0 g/100 g of
powder formula) as well as the probiotics Bifidobacterium
longum ATCC BAA-999 (Bl999) and Lactobacillus rham-
nosus CGMCC 1.3724 (LPR) each at 2 × 107 colony form-
ing units (CFUs) per gram.
The BMOS mixture used in the formulae was derived
from bovine milk whey. Briefly, an ultrafiltration perme-
ate of bovine whey including oligosaccharides such as
3′- and 6′-sialyllactose and GOS [17] was demineralised
by a combination of electrodialysis and ion exchange.
Part of the remaining lactose was then enzymatically
transformed into additional GOS using a fungal beta-
galactosidase (Enzeco® fungal Lactase, EDC, NY). The
concentration of the oligosaccharides in the final prod-
uct was determined by 2-aminobenzamide labeling as
described previously [18] and using laminaritriose as an
internal standard.
Study formulae were manufactured, packaged in identi-
cal cans, and coded by the study sponsor. The investigator,
study staff and caregivers were blinded to formula assign-
ment throughout the study.
Outcomes
The primary outcome was mean weight gain per day be-
tween 14 days and 4 months (112 days) of age. Secondary
outcomes were mean daily length and head circumference
gains from enrollment through age 4 months, measures of
gastrointestinal (GI) tolerability, stool bacterial counts,
and occurrence of adverse events (AEs).
Baseline data (sex, gestational age, age at enrollment,
mode of delivery, APGAR scores at 1 and 5 minutes, and
anthropometric measurements) were recorded at enroll-
ment. Follow-up visits to the study center were scheduledat age 14 days and at ages 1, 2, 3, 4, 6 and 12 months.
Anthropometric measurements were taken during each of
these visits. Infants were weighed nude to the nearest 10 g
on electronic scales calibrated according to the manufac-
turer’s specifications. Recumbent length was measured to
the nearest 10 mm with the full body extended and feet
flexed. Head circumference was measured approximately
2.5 cm above the eyebrows using a standard non-elastic
plastic-coated measuring tape.
GI tolerability was assessed at each visit based on diaries
caregivers kept for 3 days prior to each visit. For each of
the 3 days, caregivers recorded: (1) the volume of formula
intake or minutes of breastfeeding as well as intake of other
foods and liquids; (2) number of stools; (3) consistency of
each stool (hard, formed, soft, liquid, or watery); (4) flatu-
lence (never, sometimes, often); (5) spitting up (never, little
[≤5 ml], much [5–25 ml], very much [>25 ml]); (6) vomit-
ing (number of episodes); (7) duration of crying (<1 hour,
1–3 hours, >3 hours); (8) fussing without crying (never,
sometimes, often); (9) episodes of colic (defined as bouts of
intense, inconsolable crying with painful facial expressions
and pulling up of the legs); and (10) illnesses (eg, consti-
pation, diarrhea, ear infection, eczema, fever, respiratory
symptoms) and treatments (eg, antibiotics). Colic was also
evaluated by the investigator at each visit and recorded as
yes/no, using the following criteria: (1) paroxysms of irrit-
ability, fussing, or inconsolable crying that start and stop
without obvious cause; (2) episodes lasting 3 or more
hours per day and occurring at least 3 days per week for
at least 1 week; and (3) no failure to thrive. Potential asso-
ciated symptoms included legs drawn up towards the
abdomen [19].
At age 2 months, 5 g of fresh stool were collected from
formula-fed infants during the study visit. Approximately
1 g was transferred into tubes and stored at −20°C
until further analysis by fluorescence in situ hybridization
(FISH). FISH was used to quantify total bacterial counts
and counts of the following bacterial species: bifidobac-
teria, lactobacilli, enterobacteria, clostridia, and bacteroides
(performed by Microscreen, Groningen, Netherlands). An-
other 1 g of stool was added to a tube with 2 ml Ringer’s
solution containing 10% glycerol, and then homogenized
and stored at −20°C. Bl999 and LPR counts were quanti-
fied from these samples using culture plating technique
(performed by ATT, Piacenza, Italy).
Blood samples (approximately 2 mL) were collected at
2 months from infants in the formula groups and analyzed
for standard biochemical parameters (e.g., hemoglobin and
other iron status measures, electrolytes, blood urea nitro-
gen). The study investigator assessed the occurrence of AEs
at each visit based on interviews with caregivers. Abnor-
mal laboratory measurements also were coded as AEs. At
each visit, the investigator queried caregivers about the
occurrence of respiratory tract infection, diarrhea or other
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An episode of diarrhea was defined as ≥3 loose or watery
stools in 24 hours. The end of an episode was defined
by two consecutive non-watery stools or no stool in a
24-hour period. Symptoms of respiratory tract infections
were runny nose and chronic cough. An AE was con-
sidered serious (SAE) if it was life threatening, caused
permanent harm, resulted in hospitalization or extension
of in-patient hospital treatment, or was considered to be
medically relevant by the investigator. The investigator
assessed all AEs for relationship with study feedings. All
AEs were coded using the Medical Dictionary for Regula-
tory Activities (MedDRA).
Sample size
Sample size was based on demonstrating equivalence in
daily weight gain between the three groups with an
equivalence margin of ±3.9 g/day. However, prior to the
completion of data collection, the analysis of the primary
outcome was changed to a more conservative approach
with a noninferiority margin of −3 g/day as recommended
by the American Academy of Pediatrics (AAP) [20]. Based
on the original sample size calculation, a total of 64 infants
were needed in each group to detect a 3.9 g/day difference
in weight gain, assuming that standard deviation [SD] =
6.1 g/day (based on a previous trial performed in Palermo,
Italy [21]); α = 0.025 (due to two pairwise comparisons);
and power = 0.9. With an anticipated dropout rate of 20%,
the enrollment target for each group was 80 infants. This
target also had adequate power to evaluate noninferi-
ority of weight gain using the recommended margin
[20] of -3 g/day. Thirty infants were enrolled in the
breastfed reference group.
Statistical methods
Baseline characteristics and AEs were analyzed in all
randomized infants and all infants in the breastfed refer-
ence group. Growth, tolerance, and stool characteristics
were analyzed in all infants with post-randomization
data for these outcomes (primary analysis population).
Anthropometric outcomes also were analyzed in a per-
protocol population, which excluded infants with the
following major protocol deviations: (i) life-threatening
event during the study, (ii) hospitalization for >3 days,
(iii) consumption of more than one bottle/week of a
nonstudy formula, (iv) failure to take the assigned for-
mulae for >3 consecutive days, or (v) discontinuation
from the study before 4 months. Stool bacteria were an-
alyzed in the subset of formula-fed infants who provided
stool samples at age 2 months.
Mean weight gains (g/day) in BMOS-supplemented
and control formula groups were compared using analysis
of covariance (ANCOVA) correcting for sex, and the
97.5% two-sided confidence intervals (CIs) were adjustedaccording to Bonferroni. Weight gain was considered
noninferior if the lower bounds of the 97.5% CIs for
the differences in weight gain between the BMOS
formula and control formula groups were above −3 g/day.
Differences in mean ± SD daily gains in length and head
circumference were analyzed with ANCOVA correcting
for sex and reported with 97.5% CIs. All growth parame-
ters were compared with the World Health Organization
(WHO) Child Growth Standards [22].
Group differences in mean daily stool frequency were
evaluated using ANOVA and adjusted for multiple test-
ing using the Bonferroni method. Stool consistency was
compared between groups using logistic regression with
pair-wise comparisons adjusted for multiple testing using
the Bonferroni method. Group differences in spitting up,
vomiting, crying, being fussy, and having colic were evalu-
ated using logistic regression.
Bacterial counts were log-transformed and com-
pared between groups using the Wilcoxon rank-sum
test. Counts for bacteria that could not be detected
were considered to be at the lower limit of detection
of 106 CFU/g. P-values were adjusted for multiple
testing using the Hommel method. Statistical analyses




Three hundred and eleven healthy newborn infants were
enrolled. Of these, 281 were randomized to the formula
groups and 30 were enrolled in the breastfed reference
group (Figure 1). Groups were balanced with respect to
baseline characteristics, although the proportion of boys
and caesarean births were slightly higher in the formula
groups compared with the breastfed group (Table 1). A
total of 90 (32%) infants from the formula groups and 18
(60%) infants from the breastfed group withdrew before
the end of the study (Figure 1). Higher rates of discon-
tinuations were observed in the BMOS-supplemented
formula groups (36.4% in IF-BMOS; 34.7% in IF-BMOS +
Pro) compared with the control formula group (23.8%),
although the differences did not reach statistical signifi-
cance (p = 0.08 for IF-BMOS versus control; p = 0.14 for
IF-BMOS + Pro versus control). GI symptoms (ie, regurgi-
tation, vomiting, diarrhea, constipation, and abdominal
pain characterized by prolonged crying) were the most
common reason for study discontinuation in all three for-
mula groups: 14.3% of infants in the control group, 17.2%
in the IF-BMOS group and 13.3% in the IF-BMOS + Pro
group discontinued due to GI symptoms.
No significant differences in formula intake (mean
daily volume) were observed among the formula
groups (p > 0.05 for all comparisons). The incidence
Figure 1 Flow of study subjects. GI = gastrointestinal. GI symptoms included regurgitation, vomiting, diarrhea, constipation, and abdominal
pain/prolonged crying.
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among the formula groups (33.3%, 30.3%, and 31.6%
in control, IF-BMOS and IF-BMOS + Pro, respectively);
5 (16.7%) infants in the breastfed group used antibiotics
during the study.Table 1 Infants’ baseline characteristics
Control N = 8
Sex, no. (%) Girls 33 (39.3)
Boys 51 (60.7)
Delivery Mode, no. (%) Natural 33 (39.3)
Caesarean 51 (60.7)
Gestational Age, weeks, mean (SD) 39.2 (1.1)
Age at enrollment, days, mean (SD) 4.5 (3.2)
1-minute APGAR score, median (min-max) 9.0 (6.0-10.0)
5-minute APGAR score, median (min-max) 10.0 (8.0-10.0)
Weight, kg, mean (SD) 3.3 (0.4)
Height, cm, mean (SD) 49.4 (1.7)
Head Circumference, cm, mean (SD) 34.4 (1.2)
Min-max =minimum-maximum; SD = standard deviation.Growth
Mean daily weight gain among formula-fed infants dur-
ing the first 4 months of the study was between 30–
32 g/day (Table 2). The mean difference in daily weight
gain between each of the BMOS formula groups and the4 IF-BMOS N = 99 IF-BMOS + Pro N = 98 Breastfed N = 30
45 (45.5) 42 (42.9) 16 (53.3)
54 (54.5) 56 (57.1) 14 (46.7)
43 (43.4) 41 (41.8) 14 (46.7)
56 (56.6) 57 (58.2) 16 (53.3)
38.9 (1.3) 39.0 (1.3) 39.1 (1.3)
5.4 (4.0) 5.0 (3.6) 5.3 (3.3)
9.0 (4.0-10.0) 9.0 (0.0-10.0) 9.0 (5.0-10.0)
10.0 (5.0-10.0) 10.0 (7.0-10.0) 10.0 (6.0-10.0)
3.3 (0.4) 3.2 (0.4) 3.4 (0.4)
49.4 (1.8) 49.4 (1.8) 49.4 (1.6)
34.3 (1.1) 34.1 (1.4) 34.4 (1.2)
Table 2 Changes in anthropometric measurements between 14 days and 4 months of age













Weight gain, g/day, mean (SD) 30.3 (6.1) 31.6 (6.4) 30.1 (6.1) 30.2 (6.2) 31.5 (6.5) 30.5 (6.3)
Difference in weight gain compared









Length gain, mm/day, mean (SD) 1.07 (0.17) 1.08 (0.19) 1.05 (0.19) 1.07 (0.17) 1.08 (0.19) 1.06 (0.20)
Difference in length gain compared to









HC gain, mm/day, mean (SD) 0.57 (0.1) 0.56 (0.1) 0.55 (0.09) 0.58 (0.10) 0.57 (0.10) 0.56 (0.09)
Difference in HC gain compared to control,









CI = confidence interval; HC = head circumference; SD = standard deviation; SE = standard error.
*p > 0.05 for all comparisons with control.
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bound of the 97.5% CI of the difference in mean daily
weight gain between the control and BMOS formula
groups during this period was above the pre-set margin
of −3.0 g/day. During the same period, infants in the
breastfed group had a mean ± SD daily weight gain of
30.3 ± 5.6 g/day. Results were similar in the primary and
per protocol analyses (Table 2).
Mean daily gains in length and head circumference
during the first 4 months showed no significant differ-
ences between the control and BMOS formula groups
(p > 0.05 for all comparisons, Table 2). Compared with
WHO growth standards, infants in all groups grew nor-
mally throughout the study. Mean values for all growth
measures through age 4 months were within 0.5 SD of
the WHO median value (Figure 2).
GI tolerability
Daily stool frequency in the IF-BMOS (mean ± SD, 2.6 ±
0.9 stools/day) and IF-BMOS + Pro groups (2.4 ± 0.8
stools/day) was significantly higher than in the control
group (1.7 ± 0.7 stools/day, mean difference ± SE: −0.92 ±
0.13 [95% CI: −1.22 to −0.61] and −0.65 ± 0.13 [95%
CI: −0.96 to −0.35], respectively, p < 0.0001 for compari-
sons with BMOS formula groups). Breastfed infants had
3.0 ± 0.5 stools/day. Stool consistency distributions for
each group are shown in Figure 3. Infants fed the control
formula were more likely to have harder stools than those
fed the IF-BMOS (odds ratio [OR]: 5.06 [95% CI: 1.33 to
19.32], p = 0.0003) or IF-BMOS + Pro (OR: 6.55 [95% CI:
1.49 to 28.78], p = 0.0001) formulae.
No significant differences were observed between the
control and BMOS formula groups in caregivers’ reports
of flatulence, vomiting, spitting up, crying, fussing, and
colic (p-values ranged from 0.19 to 0.97). However, the
incidence of investigator-diagnosed colic was lower in
the control group, compared with the IF-BMOS group
(OR 0.38; 95% CI 0.18, 0.81; p = 0.01). The incidence ofinvestigator-diagnosed colic was not significantly differ-
ent in the control and IF-BMOS + Pro groups (OR 0.56;
95% CI 0.25, 1.24; p = 0.15).
Stool bacterial counts
Stool samples were available from 24 (28.6%) infants in
the control group, 18 (18.2%) in the IF-BMOS group,
and 29 (29.6%) in the IF-BMOS + Pro group. All of the
stool samples from infants in the IF-BMOS + Pro group,
and approximately 80% of the samples from the control
and IF-BMOS groups, had detectible bifidobacteria
(Table 3). Lactobacillus species were detectable in nearly
all of the stool samples from the IF-BMOS + Pro group.
In contrast, less than 10% of samples from the control
group and less than 20% from the IF-BMOS group had
detectable levels of these species (Table 3). Clostridia
were detected in a higher percentage of stool samples
from the control group compared with either of the
BMOS formula groups, and Bacteroides were detected in
an approximately equal proportion in samples from all
three groups (Table 3). Enterobacteria were detected in
>95% of the samples from the control group and 100%
of the samples from the BMOS-supplemented groups.
Bifidobacteria and lactobacilli counts were higher in
the BMOS formula groups than in the control group,
though only the difference between the control and
IF-BMOS + Pro groups was significant (Table 4). By
contrast, clostridia counts were significantly higher in
the control group compared with either of the BMOS
formula groups (Table 4). Enterobacteria and Bacteroides
counts were not significantly different between any of the
groups (p > 0.1, Table 4). Bl999 was not detected in any of
the samples from the IF-BMOS + Pro group, whereas LPR
was detected in 16 of 29 samples.
Adverse events
One hundred and twenty-five (45%) infants had at least
one AE during the study: 36 (46%) in the control group,
Figure 2 Mean growth measurements of infants relative to World Health Organization Growth Standards. Bars indicate standard deviations.
Mean head circumference z-score at 5 months excludes the z-score of 1 infant with an implausible value (z-score = 40) at that time point only.
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BMOS + Pro group, and 8 (26.7%) in the breastfed group
(Table 5). No significant differences in the frequency of
AEs were observed between groups. A total of 26 SAEs
were reported in 25 infants during the 4-month inter-
vention period. None of these were considered related to
the study formulae. Hematology and blood biochemical
analyses (performed in about 1/3 of formula-fed infants)
were normal.Discussion
In the present study we evaluated the safety of two
infant formulae containing BMOS, an oligosaccharide
mixture derived from bovine milk. In general, oligosac-
charides are added to infant formulae as ingredients to
enhance functional properties, specifically modulation of
stool frequency and consistency as well as bifidogenic
and anti-pathogen properties. The oligosaccharides cur-
rently in use in infant formulae are limited primarily to
Figure 3 Infant stool consistency. Hard (hatched bars), formed (dotted bars), soft (grey bars), liquid (white bars), and watery (black bars). Bars
indicate standard deviations.
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published report of the use of BMOS in infant formulae.
We demonstrated that infant formula supplemented
with either BMOS alone or BMOS and the probiotics
Bl999 and LPR met the primary safety outcome and thus
provides adequate nutrition for normal growth in healthy
term infants. Infants exclusively fed BMOS-supplemented
formulae had weight gain similar to those fed a control
formula without BMOS. The lower bound of the 97.5% CI
of the difference in mean daily weight gain between the
control and BMOS formula groups was above the pre-set
margin of −3.0 g/day indicating noninferior growth in
infants fed BMOS-supplemented formulae. Furthermore,
we showed that weight, length, and head circumference
measurements during the first 4 months of life were simi-
lar to WHO growth standards [20], underscoring the suffi-
ciency of these formulae for normal growth. These results
are consistent with our previous study demonstrating the
safety of a synbiotic formula containing the probiotics
B1999 and LPR with a combination of GOS and FOS [21].
Although the primary analysis in the present study in-
cluded slightly fewer infants than the estimated number
needed from the sample size calculation, it is unlikely that








Total bacteria 24 (100) 18 (100) 29 (100)
Bifidobacteria 19 (79.2) 15 (83.3) 29 (100)
Lactobacilli 2 (8.3) 3 (16.7) 28 (96.6)
Enterobacteria 23 (95.8) 18 (100) 29 (100)
Clostridia 20 (83.3) 8 (44.4) 13 (44.8)
Bacteroides 5 (20.8) 3 (16.7) 5 (20.8)more infants in the IF-BMOS group would change the
results of the analysis in a meaningful way.
The higher stool frequency observed in the BMOS-
supplemented groups is similar to the effects reported in
previous studies of oligosaccharides added to infant for-
mula [21,23]. Stool frequency in the BMOS formula
groups was slightly lower than in the breastfed group
suggesting an effect more like that in breastfed infants.
The lower frequency of hard stools in the BMOS for-
mula groups compared with the control group may also
suggest better tolerability of formula containing BMOS
either with or without probiotics.
Our observation of a higher incidence of investigator-
diagnosed colic in the IF-BMOS group compared with
control may be due to the level of oligosaccharides
added to the formula, which was somewhat higher than
levels used previously [21,23]. The study did not find a
statistically significant difference in risk of colic between
the control and IF-BMOS + Pro formula, which sug-
gests the possibility that the risk of colic attributable
to oligosaccharides may have been modulated in a
favorable direction by the addition of the probiotics. Alter-
natively, the lack of significance may be due to inadequate
power for this particular comparison. Additional studies
are planned with lower levels of BMOS.
The high number of dropouts, especially in the two
test groups, may have been related in part to the higher
incidence of colic and other GI symptoms in those groups,
as these could have contributed to parents’ decisions to
discontinue participation in the study. Although the dif-
ferences in discontinuation rates between the BMOS-
supplemented groups and the control group did not reach
statistical significance, the study may have had inadequate
power to detect such differences.
Bifidobacteria and lactobacilli were detected in a larger
proportion of infants fed the formula supplemented
Table 4 Stool bacterial counts (log10 colony forming units/g) at age 2 months
Control n = 24 IF-BMOS n = 18 IF-BMOS + Pro n = 29
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Total 10.21 (0.3) 10.29 (10.04-10.41) 10.32 (0.4) 10.32 (9.30-10.80) 10.34 (0.4) 10.44 (10.16-10.61)
Bifidobacteria 8.80 (1.7) 9.52 (7.68-10.23) 9.45 (1.8) 10.31 (9.36-10.55) 9.87 (1.2) 10.37 (9.89-10.56)*
Lactobacilli 6.13 (0.4) 6.00 (6.00-6.00) 6.27 (0.8) 6.00 (6.00-6.00) 7.68 (0.7) 7.83 (7.14-8.31)*
Enterobacteria 8.83 (0.9) 9.15 (8.58-9.31) 8.61 (0.8) 8.77 (8.06-9.03) 8.60 (0.7) 8.75 (8.31-9.03)
Clostridia 8.49 (1.4) 8.72 (7.46-9.74) 6.97 (1.3) 6.00 (6.00-7.97)* 7.01 (1.3) 6.00 (6.00-7.83)*
Bacteroides 6.37 (0.8) 6.00 (6.00-6.00) 6.30 (0.7) 6.00 (6.00-6.00) 6.48 (1.2) 6.00 (6.00-6.00)
SD = standard deviation; IQR = interquartile range.
*Significant difference compared with control (Wilcoxon rank sum <0.05).
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fed control formula. Furthermore, bifidobacteria and
Lactobacillus counts were higher in infants fed the
IF-BMOS + Pro formula, compared with those fed the
control formula. A similar trend was observed in the IF-
BMOS group with respect to a higher bifidobacteria count
and a higher proportion of infants with detectable bifido-
bacteria compared with control; although the differences
were not statistically significant. Given the exploratory na-
ture of these analyses and the limited number of stool
samples, the lack of a significant effect could be due to
limited power. Furthermore, without baseline stool sam-
ples, we cannot exclude the possibility that differences in
bacterial counts at baseline (e.g., due to differences in
breastfeeding before day 14) was a source of confounding.Table 5 Number of serious adverse events occurring









Pneumonia 3 2 1 1
Bronchitis 2 0 2 0
Apnoea 0 1 0 0
Dyspnoea 0 1 0 0
Upper respiratory
tract infection
0 0 1 0
Abdominal pain 2 0 0 0
Gastroenteritis 2 0 0 0
Diarrhea 0 1 0 0
Gastroesophageal
reflux
0 0 0 1
Stupor 1 0 0 0
Convulsions 0 0 1 0
Hernia inguinal 0 1 1 0
Sudden infant death
syndrome
0 0 1 0
Urinary tract infection 0 0 1 0
Total 10 6 8 2
MedDRA =Medical Dictionary for Regulatory Activities.However, this seems unlikely as infants were randomly
assigned to the formula groups, and other baseline charac-
teristics were balanced across these groups.
These results are consistent with a previous study that
reported a bifidogenic effect of an infant formula supple-
mented with a mixture of GOS and FOS [24]. The
present study also found lower clostridia counts in both
BMOS-supplemented formula groups compared with
the control group. This finding further supports the hy-
pothesis that infant formula containing BMOS alone or
BMOS with probiotics may have beneficial effects on
the composition of the infant gut microbiota. Nonethe-
less, these results require confirmation in studies specif-
ically focused on changes in gut microbiota as a primary
outcome.
Interestingly, although bifidobacteria counts appeared
slightly higher in the IF-BMOS + Pro group compared
with the IF-BMOS group, the difference was not signifi-
cant. This finding suggests that, at the concentration
used in this study, the addition of Bl999 may not signifi-
cantly increase total bifidobacteria counts above the effect
of BMOS and a higher concentration may be needed
to obtain an additional effect. Alternatively, collection
of stools from a greater number of infants may have
been needed to detect a significant difference in bifidobac-
teria counts between the two BMOS formula groups.
Stool samples were available from only one third of the
formula-fed infants, which may have limited statistical
power to detect a difference between groups.
We were unable to detect Bl999 in stool from infants
fed IF-BMOS + Pro, which contained this probiotic,
although total bifidobacteria counts were higher with this
formula compared with control. It is possible that plating
method used to detect B1999 may not have been sensi-
tive enough given the higher background level of other
bifidobacteria strains. On the other hand, infants fed IF-
BMOS + Pro had significantly higher lactobacilli counts
compared with infants in both the control and IF-BMOS
groups, presumably due to the presence of LPR (which
was detected in 16/29 stool samples) in the formula. The
Meli et al. BMC Pediatrics  (2014) 14:306 Page 10 of 11observation that Lactobacillus counts were not affected
by the addition of BMOS to infant formulae is consist-
ent with the purported effect of prebiotics primarily on
bifidobacteria.
An important limitation of this study is the high rate
of withdrawal, which reduced the study’s power to evaluate
secondary outcomes. Nonetheless, the study had adequate
power to evaluate the primary outcome of the study and
thus the results showing noninferiority of weight gain with
BMOS-supplemented formula, as well as adequate overall
growth, are robust.Conclusions
In conclusion, we have shown that (i) bovine milk can
be used as a source of oligosaccharides for infant for-
mula and (ii) BMOS-supplemented formula provides
adequate nutrition for normal growth in healthy term
infants. Further studies are needed to fully explore the
digestive tolerance of BMOS formula. The addition of
BMOS to infant formula resulted in more frequent, less
hard stools compared with control formula; however, a
higher incidence of colic was also detected. This effect
was likely due to the dosage of the prebiotic and studies
with lower levels of BMOS are planned. The present
study also revealed positive trends in stool bacterial counts
in the infants fed BMOS-supplemented formulae. Al-
though confirmatory studies that are designed to evaluate
the effects of BMOS on fecal bacteria levels are needed,
these results suggest that BMOS-supplemented infant
formula may be able to beneficially modulate the compos-
ition of the gut microbiota in formula-fed infants.
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